CPX-351 in Down Syndrome–Associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial

CPX-351 in Down Syndrome–Associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial Authors: Stephanie Laszig; Antonia Diederichs, MD; Emilia Salzmann-Manrique; Konstantin Schuschel; José Gonçalves-Dias, PhD ; Hasan Issa, PhD; Milica Miladinovic, MD; Eva Rettinger, MD; Sibylle Wehner; Hermann Kreyenberg, PhD; Melanie Bremm, PhD; Sabine Hünecke, PhD; Helena Kerp, PhD; Katharina Waack-Buchholz; Felicitas R. Thol, MD; Bianca F. Goemans, MD, PhD; Barbara De Moerloose, MD, PhD; Heidrun Boztug, MD; Nastassja Scheidegger, MD; Katarzyna Pawińska-Wąsikowska, MD; Dirk Reinhardt, MD; Jan-Henning Klusmann, MD https://www.medscape.org/viewarticle/1003212?sso=true&impID=8033435&uac=148436CN&src=wnl_tpal_260116_mscpedu